RxDoctor Payments Data

Leon Shein, MD

Nephrology · Brooklyn, NYNPI 1215004858

Payments from drug & device makers

$17,196in general payments, 2019–2025

Across 180 payments — averaging $95.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$13K
  • Bayer$764
  • Fresenius USA Marketing, Inc.$602
  • AstraZeneca$581
  • GSK$297
  • Mallinckrodt Enterprises LLC$180
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$11,39566%
  • Travel & lodging$1,0936%
  • Food & beverage$4,65227%
  • Education$550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,196 in reported general payments places this provider in the 85th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$113,626
Medicare patients
339
Services billed
1,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide157$243,277
Diclofenac Sodium11$26,173
Sevelamer Carbonate89$15,298
LokelmaSodium Zirconium Cyclosilicate18$12,006
FarxigaDapagliflozin Propanediol14$10,853
OzempicSemaglutide11$10,480
EliquisApixaban13$8,250
ProsolParenteral Amino Acid 20% No.137$4,627
Nifedipine ErNifedipine178$3,800
Labetalol Hcl115$2,993
Clonidine21$1,929
Calcium Acetate30$1,372
Albuterol Sulfate HfaAlbuterol Sulfate32$1,012
Isosorbide Dinitrate18$694
Hydralazine Hcl71$645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$602$243,277157 claims
AstraZenecaLokelma, Farxiga$581$22,85932 claims
Novo NordiskOzempic$20$10,48011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 nephrology providers in New York.

Other nephrology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →